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symposium on clinical and translational medicine
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Michael Liebman7, Chunxue Bai2, Ching-Wan Lam8, Gyorgy Marko-Varga9, Thomas E Fehniger9,
Roland Andersson9 and Xiangdong Wang1,2*
Abstract
Background: Clinical translational medicine (CTM) is an emerging area comprising multidisciplinary research from
basic science to medical applications and entails a close collaboration among hospital, academia and industry.
Findings: This Session focused discussing on new models for project development and promotion in translational
medicine. The conference stimulated the scientific and commercial communication of project development
between academies and companies, shared the advanced knowledge and expertise of clinical applications, and
created the environment for collaborations.
Conclusions: Although strategic collaborations between corporate and academic institutions have resulted in a
state of resurgence in the market, new cooperation models still need time to tell whether they will improve the
translational medicine process.
Introduction
Clinical translational medicine (CTM) is an emerging
area comprising multidisciplinary research from basic
science to medical applications and entails a close col-
laboration among hospital, academia and industry [1].
CTM is to bridge the divide between health informatics
‘bench research’ and the application of informatics in
clinical and health care settings [2]. The critical care
community is beginning to adopt an increasingly transla-
tional approach to research, drug development and
early-phase clinical trials [3].
The 2012 Sino-American Symposium on Clinical and
Translational Medicine (SAS-CTM) served as one of the
milestone conferences on CTM and was organized by
Chinese Academy of Engineering, Chinese Academy of
Medical Sciences, The U.S. National Institutes of Health
Clinical Center, and Global MD Organization. As a part
of 2012 SAS-CTM, session seven, Project Development
and Promotion in Translational Medicine, was co-
chaired by Dr. Roland Anderson, Professor of Depart-
ment of Surgery, Clinical Sciences,Medical Faculty, Lund
University and Dr. Xiangdong Wang, Professor of Medi-
cine and Director, Biomedical Research Center, Fudan
University Zhongshan Hospital. The Session focused on
new models for project development and promotion in
translational medicine.
Findings
Current situation of translational medicine
Translational medicine is a growing and emerging area that
integrates basic, social, clinical and political science to-
gether to efficiently improve patient care and outcomes.
However, we should know there are lessons to be learned
about the best approaches for the promotion of transla-
tional medicine [4]. So, we need to have a general know-
ledge of the current situation of translational medicine first.
Dr. Ena Wang, Senior Staff Scientist, Director of Mo-
lecular Science of DTM-CC and Associate Director of
Center for Human Immunology of NIH, presented a sys-
tem biology approach in current translational medicine
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application. She shared her studies that they used trans-
lational medicine methodology to characterize the
human immune responsiveness in both healthy indivi-
duals and the cancer patients which were adopting im-
munotherapies. She summarized the process from
observing clinical phenomenon to generating hypothesis
and finishing data interpretationwhich let us have a direct
view of what is translational research.
Mr. William Rhodes, Senior Vice President of Cor-
porate Strategy and Development, Becton Dickinson &
Company, described the current role of corporate-
academic research partnerships in translational medicine,
and what might be done to improve it. The traditional
model of drug development is to focus on ‘investigator-
centric’ research; that is, healthcare companies fund
investigators to undertake clinical research of the manu-
facturers’ products. In most nations, there are regulations
that govern the ability of corporations to fund basic re-
search in hospitals and academic settings. This potentially
creates a schism between the rapid translation of new
medical discoveries to medical practice and the source of
funding that might enable it. Meanwhile, health systems
around the world are experiencing increasing pressure to
treat more patients in shorter times, with an eye towards
cost control as well as efficacy, and patients are advocating
for more rapid availability of new treatment modalities.
This approach does not promote the early study and
testing of novel therapeutic concepts based on contem-
poraneous and new experimental data – it can, in fact,
impede the movement of new treatments and diagnostics
from laboratory to patient. Given the rapid and import-
ant advances in basic cellular research, coupled with sin-
gle cell genomics, proteomics and the like, it seems likely
that important new discoveries, which can be applied to
the effective diagnosis and treatment of disease, may lan-
guish as they proceed along a protracted timeline, or
worse yet, never make it from lab to patient. Industry
must, then, adopt a more progressive model, working
with academia and regulators, to foster more rapid trans-
lation of laboratory advances to clinical practice, in order
to become more relevant and competitive. Without this,
the schism mentioned above will continue to widen, stal-
ling the development of new effective diagnostic tools
and disease treatments.
The reports from these two professors gave us a general
idea of the current situation of translational medicine, but
we still need to select the right collaboration model and
the developing way of our translational program.
New collaboration models
Collaboration between academia and industry
How might we interact among stakeholders to optimally
integrate health care delivery, academic research and the
healthcare industry to improve the efficacy of truly
translational medicine? What are the challenges?? In its
simplest form, the solution lies in closer communication
and integration among the various players, including
product developers, academic researchers, healthcare
providers and governments. There is a new model emer-
ging to address this. Targeted drug development is one
example of success in clinical and translational medicine.
Several countries are now promoting the integration of
their previously separated health and academic sectors.
For example, in the U.K., Germany, Australia, Brazil,
and Singapore, institutes have been established that
create a strong link with industry and cut across vari-
ous areas of science and medical practice. Meanwhile,
academic institutions and government research centers
are emerging as true partners with industry in the
drug discovery and evaluation process. An example is
the proposed National Center for Advancing Transla-
tional Science (NCATS) at the US NIH, which will be-
come a key catalyst, integrator and leader to insure the
interface of government, academic institutions and in-
dustry to promote translational medicine. In addition,
pharmaceutical, biotech and other healthcare product
developers are increasingly entering milestone-based
funding agreements with academia and clinical investiga-
tors, sharing the risk of product development at a much
earlier stage, in order to more rapidly move scientific dis-
coveries to the treatment of patients and ultimately,
commercialization.
Partnership business models
While there are various forms and structures of partner-
ship business models, one that has proven successful has
the product development organization (company) estab-
lishing a more integrated and flexible external network
of academic experts. Such an example is Chorus, an au-
tonomous division of Eli Lilly and Company [5], that is
an early phase drug development group that cost-
effectively advances candidate molecules from discovery
through clinical proof of concept (PoC). In the seven
years since its inception, Chorus has advanced two
dozen molecules into development from discovery
through early phase clinical study in patients. Another
model calls for industry sharing its resources with mul-
tiple medical researchers and clinicians in Centers of Ex-
cellence (COEs), an example of which is the Shanghai
Clinical Immunology Research Center [6], founded by
Becton Dickinson & Co. (BD) and Zhongshan Hospital
Fudan University. This COE allows researchers to share
the most advanced and specialized laboratory equipment
and clinical samples (Figure 1). Another approach is to
develop broad and flexible institution-wide collabora-
tions, a representative of which is Pfizer’s Center for
Therapeutic Innovation (CTI) [7], an entrepreneurial re-
search unit at Pfizer dedicated to establishing global
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partnerships between Academic Medical Centers
(AMCs) and Pfizer to focus on translational medicine.
CTI laboratory staff includes Pfizer employees working
side-by-side with leading basic and translational science
investigators and post-docs from the AMCs. CTI estab-
lished partnerships with 20 leading academic medical
centers across the United States and supports collabora-
tive projects from four dedicated labs in Boston, New
York City, San Francisco, and San Diego. CTI received
over 300 proposals from its first round of applications,
and to-date has selected approximately 20 programs to
initiate in partnership with the proposing PIs. Funded
programs span a broad range of therapeutic areas, in-
cluding oncology, inflammation, infectious disease, car-
diovascular and metabolic disease.
Trends of developing translational medicine
In this conference, our major focus is to develop the
multidisciplinary approach and academic/industry part-
nership in this translational medicine area in order to
improve our understanding of diseases, and enhance
cost-effective decision making in exploratory develop-
ment [8]. During the conference, two professors shared
their successful experiences in translational medicine.
Dr. Michael N. Liebman, CEO of Strategic Medicine Inc,
described the clinical and translational medicine treat-
ment in rare diseases and pediatrics that are being car-
ried out in the United States and extended to Europe
and potentially China [9]. Dr. Wei Wang, Professor of
School of Medical Sciences, Edith Cowan University,
Perth, Australia, and he is also the Dean of School of
Public Health and Family Medicine, Capital Medical
University and Professor of the Chinese Academy of
Sciences, Beijing, China, described the translational
medicine research in traditional Chinese medicine,
mainly focusing on suboptimal-health status ‘a new
health dimension for translational medicine” [10,11].
These two successful cases let us have full confidence in
the development of translational medicine and get an
idea of the developing trend of translational medicine.
From biobanking to precision medication
Dr. Gyorgy Marko-Varga, Professor of Lund University,
described the biobanking facility in his hospital. To set
up a specimen bank requires the collection of specimens
while strictly following good clinical practice principles.
The specimens collected have to be well identified and
kept in strict environmental controlled facilities from the
time of collection to the final storage [12]. Though the
establishment of biobankis not easy, the benefit to clin-
ical research is obvious such as promoting precision
medication. Professor described his studies in individua-
lized medication from screening drug delivery to gradual
realization of precision medicine, thus ensuring patients
the best and the most effective drugs in the early stage
of diseases. We can obtain many specimens from bio-
bank with related information that can be used in clin-
ical translational research, thus realizing precision
medicine which provides good prospects for establishing
rational use of drugs, improving curative effects and re-
ducing adverse reactions.
From bioinformatics to dynamic biomarker network
Some complex diseases are not caused by the matur-
ation of single gene or single protein. It is an integration
of networks, so we can’t diagnose these diseases depend-
ing only based on one or several genes and proteins. Nu-
merous genetic and genomic datasets or proteomic
datasets related to complex diseases have been made
available during the last decade [13].
Dr. Ching-Wan Lam, Professor of the University of
Hong Kong, described his studies of omics-based
Figure 1 Success Story: Shanghai clinical immunology research center. It has supported molecular immunology training program developed
collaboratively between BD and Shanghai Zhongshan Hospital partners. It has proven very popular with both clinical fellows and industry, and
acted as a catalyst for greater industry engagement at translational medicine.
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medicine. He explained the concept of metabolomics.
Metabolomics can be defined as the field of science that
deals with the measurement of metabolites in an organ-
ism and studies the physiological processes and reactions
to various pathological stimuli. Metabolomic analysis
can be translated into clinical medicine in terms of dis-
ease identification, early disease detection and screening
through metabolomic analysis of human biofluids.
A number of methodologies and computational
programs have been developed to integrate selected pro-
teins into the knowledge-based networks via the com-
bination of genomics, proteomics and bioinformatics
[14]. Dr. Francesco Marincola, Chief of the Infectious
Disease and Immunogenetics Section in the Department
of Transfusion Medicine at the Clinical Center of the
National Institutes of Health, reported his studies in
finding network biomarkers in the metastatic cancer
model. Bioinformatics analysis can provide a valuable
molecular basis for systematic interpretation of the
mechanism underlying metastasis where potential protein
markers could be characterized [15].
The studies of these two professors made us have full
confidence in the promotion of translational medicine in
this field.
From internet of things to telemedicine
Internet of Things is one of the major communication
advances in present time that links the internet with
everyday sensors and working devices for an all –IP
based architecture [16]. Internet of Things in Medicine
is broadly recognized as a potentially important tool for
transforming medical care and public health [17].
Internet of Things in Medicine includes many kinds of
sensors within medical devices, combines the Internet of
Things with the current internet, thus perfectly achiev-
ing the integration of hospitals, patients and medical
devices and facilitating a totally new modern medical
mode.
Telemedicine is the application of telemetry in the prac-
tice of medicine. To a comprehensive definition is in usage
of exchanged medical information through electronic net-
works to improve a patient’s education, healthcare provi-
der’s education, and patient care [18]. Dr. Chunxue Bai,
Director of Shanghai Respiratory Research Institute,
described his telemedicine mode to us--Cell Phone Based
Remote Monitoring System for Lung Function. This in-
vention can improve COPD management, asthma man-
agement and ICU ventilator management. It will let
people diagnose diseases earlier, receive treatments earlier
thus reducing the risks and even saving lives.
Our current complex health-care systems are fragmen-
ted, and their functioning, both in terms of efficiency
and quality, are plagued by multiple discontinuities. But
E-Health has the potential to ease transitions between
the many settings and stakeholders of healthcare [19].
So, application of Internet of Things in Medicine is shall
to be more benefit to people, it will be a developing
trend in translational medicine in future.
Conclusions
On the basis of these professors’ reports, we have had a
general idea of the current situation, the new collaboration
models and the future developing trend of the translational
medicine, shown in Figure 2. The conference stimulated
Figure 2 Translational medicine is a growing and merging area to integrate basic, social, clinic and political sciences together to
efficiently improve patient care and outcomes. We should have a general idea of the current situation, developing trend and new
collaboration models of translational medicine thus we can find a right way to promote translational program.
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the scientific and commercial communication of project
development between academies and companies, shared
the advanced knowledge and expertise of clinical applica-
tions, and created the environment for collaborations. It
was also a golden opportunity for both academic and
company scientists to explore the potential for further
collaborations and support for each other. Although
strategic collaborations between corporate and aca-
demic institutions have resulted in a state of resurgence
in the market, new cooperation models still need time
to tell whether they will improve the translational
medicine process.
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